Illumina Inc. (ILMN)
-NasdaqGS | Prev Close: | 70.69 |
|---|
| Open: | N/A |
|---|
| Bid: | 50.66 x 100 |
|---|
| Ask: | 2,000.00 x 200 |
|---|
| 1y Target Est: | 62.77 |
|---|
| Beta: | 0.86 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 37.77 - 77.11 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,372,050 |
|---|
| Market Cap: | 8.79B |
|---|
| P/E (ttm): | 90.86 |
|---|
| EPS (ttm): | 0.78 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 6 Ways You Can Profit From Molecular Diagnosticsat Seeking Alpha(Wed, 22 May)
- Roche, Sigma teamed up for failed Life Technologies bid: sourcesat Reuters(Wed, 22 May)
- Roche, Sigma teamed up for failed Life Technologies bid -sourcesat Reuters(Wed, 22 May)
- Opportunities in Hepatitis C and Genomic Technologies: a Wall Street Transcript Interview with David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.Wall Street Transcript(Wed, 22 May)
- Splicing & Dicing Myriad Genetics Amidst the Angelina Jolie Disclosureat Motley Fool(Wed, 22 May)
- QIAGEN Downgraded to Strong SellZacks(Wed, 22 May)
- Sequenom shares advance as analyst lifts ratingAP(Tue, 14 May)
- Illumina surges on 1Q stronger income and salesAP(Wed, 24 Apr)
- Illumina takes 1Q loss on Syntrix chargeAP(Tue, 23 Apr)
- Roche joins Life Tech auction, KKR and H&F team up -sourcesReuters(Wed, 20 Mar)
Key Statistics
| Forward P/E (1 yr): | 35.70 |
|---|
| P/S (ttm): | 7.29 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.68 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.39 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | 2.45 |
|---|
Business Summary
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa.
View More